<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39121972</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>20</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-2742</ISSN><JournalIssue CitedMedium="Internet"><Volume>89</Volume><Issue>4</Issue><PubDate><Year>2024</Year><Month>Oct</Month></PubDate></JournalIssue><Title>The Journal of infection</Title><ISOAbbreviation>J Infect</ISOAbbreviation></Journal><ArticleTitle>Prevalence, risk factors and characterisation of individuals with long COVID using Electronic Health Records in over 1.5 million COVID cases in England.</ArticleTitle><Pagination><StartPage>106235</StartPage><MedlinePgn>106235</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jinf.2024.106235</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0163-4453(24)00169-5</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">This study examines clinically confirmed long-COVID symptoms and diagnosis among individuals with COVID in England, aiming to understand prevalence and associated risk factors using electronic health records. To further understand long COVID, the study also explored differences in risks and symptom profiles in three subgroups: hospitalised, non-hospitalised, and untreated COVID cases.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A population-based longitudinal cohort study was conducted using data from 1,554,040 individuals with confirmed SARS-CoV-2 infection via Clinical Practice Research Datalink. Descriptive statistics explored the prevalence of long COVID symptoms 12 weeks post-infection, and Cox regression models analysed the associated risk factors. Sensitivity analysis was conducted to test the impact of right-censoring data.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">During an average 400-day follow-up, 7.4% of individuals with COVID had at least one long-COVID symptom after acute phase, yet only 0.5% had long-COVID diagnostic codes. The most common long-COVID symptoms included cough (17.7%), back pain (15.2%), stomach-ache (11.2%), headache (11.1%), and sore throat (10.0%). The same trend was observed in all three subgroups. Risk factors associated with long-COVID symptoms were female sex, non-white ethnicity, obesity, and pre-existing medical conditions like anxiety, depression, type II diabetes, and somatic symptom disorders.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This study is the first to investigate the prevalence and risk factors of clinically confirmed long-COVID in the general population. The findings could help clinicians identify higher risk individuals for timely intervention and allow decision-makers to more efficiently allocate resources for managing long-COVID.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Han-I</ForeName><Initials>HI</Initials><AffiliationInfo><Affiliation>Department of Health Sciences, University of York, York, UK; Institute of Health Informatics, University College of London, London, UK. Electronic address: han-i.wang@york.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Doran</LastName><ForeName>Tim</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Health Sciences, University of York, York, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crooks</LastName><ForeName>Michael G</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Hull York Medical School, York, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khunti</LastName><ForeName>Kamlesh</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Diabetes Research Centre, University of Leicester, Leicester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heightman</LastName><ForeName>Melissa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>University College London Hospitals NHS Foundation Trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gonzalez-Izquierdo</LastName><ForeName>Arturo</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Health Informatics, University College of London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qummer Ul Arfeen</LastName><ForeName>Muhammad</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Health Informatics, University College of London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Loveless</LastName><ForeName>Antony</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Patient and Public Involvement (PPI) member for STIMULATE-ICP Consortium, Institute of Health Informatics, University College of London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Banerjee</LastName><ForeName>Amitava</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Health Informatics, University College of London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Der Feltz-Cornelis</LastName><ForeName>Christina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Health Sciences, University of York, York, UK; Hull York Medical School, York, UK; Institute of Health Informatics, University College of London, London, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Infect</MedlineTA><NlmUniqueID>7908424</NlmUniqueID><ISSNLinking>0163-4453</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="Y">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004739" MajorTopicYN="N" Type="Geographic">England</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">Post SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">Prevalence</Keyword><Keyword MajorTopicYN="N">Risk factor</Keyword><Keyword MajorTopicYN="N">Symptoms</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Prof. Christina Van Der Feltz-Cornelis received travel and accommodation in UK for lectures from The Lloyd Register Foundation and honoraries from Janssen UK and royalties for books on psychiatry. Prof. Christina Van Der Feltz-Cornelis has also received grants from the National Institute for Health Research, British Medical Association, European Union&#x2019;s Horizon 2020 research programme and the Netherlands Organisation for Health Research and Development. Prof. Amitava Banerjee has received grants and/or fees from the National Institute for Health Research, British Medical Association, UK Research and Innovation, European Union&#x2019;s Horizon 2020 research and innovation programme and EFPIA, and AstraZeneca. Dr. Michael G Crooks has received grants, fees and/or non-financial support from the National Institute for Health and Care Research, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Philips, and Pfizer. Prof. Kamlesh Khunti was chair of the ethnicity subgroup of the UK Scientific Advisory Group for Emergencies (SAGE)&#xa0;and has acted as a consultant, speaker or received grants for investigator-initiated studies from Astra Zeneca and Pfizer. K.K. (chair) and A.B. are members of the National Long Covid Research Group that informs the chief medical officer for England. All other authors have no conflicts of interest to report.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>10</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>7</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>7</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>21</Day><Hour>13</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>8</Month><Day>10</Day><Hour>15</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>8</Month><Day>9</Day><Hour>19</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39121972</ArticleId><ArticleId IdType="pmc">PMC11409608</ArticleId><ArticleId IdType="doi">10.1016/j.jinf.2024.106235</ArticleId><ArticleId IdType="pii">S0163-4453(24)00169-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>National Institute for Health and Care Excellence (NICE). Scottish Intercollegiate Guidelines Network (SIGN), &amp; Royal College of General Practitioners (RCGP) COVID-19 Rapid Guide: Manag Longterm Eff COVID-19; 2022. &#x2329;https://www.nice.org.uk/guidance/ng188/resources/covid19-rapid-guideline-%20managing-the-longterm-effects-of-covid19-pdf-51035515742&#x232a;.</Citation></Reference><Reference><Citation>Nalbandian A., Sehgal K., Madhavan M.V., McGroder C., Stevens J.S., Cook J.R., et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27:601&#x2013;615.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A., Nirantharakumar K., Hughes S., Williams T., Gokhale K., Chandan J., et al. Assessment of 115 symptoms for long covid (post-covid-19 condition) and their risk factors in non-hospitalised individuals: A retrospective matched cohort study in UK primary care. Nat Med. 2022;28:1706&#x2013;1714.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre C.H., Murray B., Varsavsky T., Graham M.S., Penfold R.S., Bowyer R.C., et al. Attributes and predictors of long COVID. Nat Med. 2021;27:626&#x2013;631.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7611399</ArticleId><ArticleId IdType="pubmed">33692530</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A., Nirantharakumar K., Hughes S., Myles P., Williams T., Gokhale K.M., et al. Symptoms and risk factors for long COVID in non-hospitalized adults. Nat Med. 2022;28:1706&#x2013;1714.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9388369</ArticleId><ArticleId IdType="pubmed">35879616</ArticleId></ArticleIdList></Reference><Reference><Citation>Aiyegbusi O.L., Hughes S.E., Turner G., Rivera S.C., McMullan C., Chandan J.S., et al. Symptoms, complications and management of long COVID: a review. J R Soc Med. 2021;114:428&#x2013;442.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8450986</ArticleId><ArticleId IdType="pubmed">34265229</ArticleId></ArticleIdList></Reference><Reference><Citation>Office for National Statistics. Prevalence of Ongoing Symptoms Following Coronavirus (COVID-19) Infection in the UK; 2022. &#x2329;https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/7july2022&#x232a;.</Citation></Reference><Reference><Citation>Feldman D.E., Boudrias M.-H., Mazer B. Long COVID symptoms in a population-based sample of persons discharged home from hospital. Can J Public Health. 2022;113:930&#x2013;939.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9491248</ArticleId><ArticleId IdType="pubmed">36131218</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayoubkhani D., Khunti K., Nafilyan V., Maddox T., Humberstone B., Diamond I., et al. Post-covid syndrome in individuals admitted to hospital with covid-19: retrospective cohort study. BMJ. 2021;372:n693.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8010267</ArticleId><ArticleId IdType="pubmed">33789877</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong M.C.-S., Huang J., Wong Y.-Y., Wong G.L.-H., Yip T.C.-F., Chan R.N.-Y., et al. Epidemiology, symptomatology, and risk factors for long covid symptoms: population-based, multicenter study. JMIR Public Health Surveill. 2023</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9994465</ArticleId><ArticleId IdType="pubmed">36645453</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Feltz-Cornelis C.M., Sweetman J., Turk F., Allsopp G., Gabbay M., Khunti K., et al. Integrated care policy recommendations for complex multisystem long term conditions and long COVID. Sci Rep. 2024;14:13634.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11176166</ArticleId><ArticleId IdType="pubmed">38871773</ArticleId></ArticleIdList></Reference><Reference><Citation>Research to Spread Light on Long COVID Uncertainties. &#x2329;https://www.umu.se/en/news/research-to-spread-light-on-long-covid-uncertainties_11713455/&#x232a;.</Citation></Reference><Reference><Citation>Andersen K.M., Bates B.A., Rashidi E.S., Olex A.L., Mannon R.R., Patel R.C., et al. Long-term use of immunosuppressive medicines and in-hospital COVID-19 outcomes: a retrospective cohort study using data from the National COVID Cohort Collaborative. Lancet Rheuma. 2022;4:e33&#x2013;e41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8592562</ArticleId><ArticleId IdType="pubmed">34806036</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrett E., Gallagher A.M., Bhaskaran K., Forbes H., Mathur R., van Staa T., et al. Data resource profile: Clinical Practice Research Datalink (CPRD) Int J Epidemiol. 2015;44:827&#x2013;836.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4521131</ArticleId><ArticleId IdType="pubmed">26050254</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolf A., Dedman D., Campbell J., Booth H., Lunn D., Chapman J., et al. Data resource profile: Clinical Practice Research Datalink (CPRD) Aurum. Int J Epidemiol. 2019;48</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6929522</ArticleId><ArticleId IdType="pubmed">30859197</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H.-I., Han L., Jacobs R., Doran T., Holt R.L.G., Prady S.L., et al. Healthcare resource use and costs for people with type 2 diabetes mellitus with and without severe mental illness in England: longitudinal matched-cohort study using the Clinical Practice Research Datalink. Br J Psychiatry J Ment Sci. 2022;221:402&#x2013;409.</Citation><ArticleIdList><ArticleId IdType="pubmed">35049484</ArticleId></ArticleIdList></Reference><Reference><Citation>NHS Digital. Quality and Outcomes Framework (QOF) Indicators 2013&#x2013;14; 2013.</Citation></Reference><Reference><Citation>Thygesen J.H., Tomlinson C., Hollings S., Mizani M.A., Handy A., Akbari A., et al. COVID-19 trajectories among 57 million adults in England: a cohort study using electronic health records. Lancet Digit Health. 2022;4:e542&#x2013;e557.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9179175</ArticleId><ArticleId IdType="pubmed">35690576</ArticleId></ArticleIdList></Reference><Reference><Citation>Chisholm J. The Read clinical classification. BMJ. 1990;300:1092.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1662793</ArticleId><ArticleId IdType="pubmed">2344534</ArticleId></ArticleIdList></Reference><Reference><Citation>National Library of Medicine. Overview of SNOMED CT. &#x2329;https://www.nlm.nih.gov/healthit/snomedct/snomed_overview.html&#x232a;.</Citation></Reference><Reference><Citation>World Health Organization. ICD-10: International Statistical Classification of Diseases and Related Health Problems: Tenth Revision; 2004. &#x2329;https://apps.who.int/iris/handle/10665/42980&#x232a;.</Citation></Reference><Reference><Citation>Clinical Practice Research Datalink. CPRD GOLD SGSS January 2022. Number of unique patients = 378,135 Clinical Practice Research Datalink; 2022. &#x2329;https://doi.org/10.48329/NK4J-1P27&#x232a;.</Citation></Reference><Reference><Citation>Clinical Practice Research Datalink. CPRD Aurum SGSS January 2022. Number of unique patients = 1,720,744 Clinical Practice Research Datalink; 2022. &#x2329;https://doi.org/10.48329/BEJK-QA30&#x232a;.</Citation></Reference><Reference><Citation>Davis H.E., Assaf G.S., McCorkell L., Wei H., Low R.J., Re&#x2019;em Y., et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021;38</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>NHS England. Post-COVID Syndrome (Long COVID). &#x2329;https://www.england.nhs.uk/coronavirus/post-covid-syndrome-long-covid/&#x232a;.</Citation></Reference><Reference><Citation>NHS. Long-term Effects of COVID-19 (Long COVID). &#x2329;https://www.nhs.uk/conditions/covid-19/long-term-effects-of-covid-19-long-covid/&#x232a;.</Citation></Reference><Reference><Citation>Public Health England Guidance on Social Distancing for Everyone in the UK Gov UK; 2020. &#x2329;https://www.gov.uk/government/publications/covid-19-guidance-on-social-distancing-and-for-vulnerable-people/guidance-on-social-distancing-for-everyone-in-the-uk-and-protecting-older-people-and-vulnerable-adults&#x232a;.</Citation></Reference><Reference><Citation>NHS. Who is at High Risk from Coronavirus (COVID-19). &#x2329;https://www.nhs.uk/conditions/coronavirus-covid-19/people-at-higher-risk/who-is-at-high-risk-from-coronavirus/&#x232a;.</Citation></Reference><Reference><Citation>UK Health Security Agency and Department of Health and Social Care. COVID-19: guidance for people whose immune system means they are at higher risk. &#x2329;https://www.gov.uk/government/publications/covid-19-guidance-for-people-whose-immune-system-means-they-are-at-higher-risk&#x232a;.</Citation></Reference><Reference><Citation>T. Smith and B. Smith, Graphing the Probability of Event as a Function of Time Using Survivor Function Estimates and the SAS&#xae; System&#x2019;s PROC (https://www.lexjansen.com/wuss/2000/WUSS00109.pdf).</Citation></Reference><Reference><Citation>Johnston R., Jones K., Manley D. Confounding and collinearity in regression analysis: a cautionary tale and an alternative procedure, illustrated by studies of British voting behaviour. Qual Quant. 2018;52:1957&#x2013;1976.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5993839</ArticleId><ArticleId IdType="pubmed">29937587</ArticleId></ArticleIdList></Reference><Reference><Citation>Fine J.P., Gray R.J. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496&#x2013;509.</Citation></Reference><Reference><Citation>A. Banerjee, L. Pasea, A. Gonzalez-Izquierdo, C. Van der Feltz-Cornelis, H.-I. Wang, M. Alizadeh Mizani, et al., Characterizing long COVID patients across pre-existing physical and mental health conditions: risk profiling using Electronic Health Records in the United Kingdom, CPRD approved studies, 2022, (https://www.cprd.com/approved-studies/characterizing-long-covid-patients-across-pre-existing-physical-and-mental-health).</Citation></Reference><Reference><Citation>Thompson E.J., Williams D.M., Walker A.J., Mitchell R.E., Niedzwiedz C.L., Yang T.C., et al. Long COVID burden and risk factors in 10 UK longitudinal studies and Electronic Health Records. Nat Commun. 2022;13:3528.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9240035</ArticleId><ArticleId IdType="pubmed">35764621</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker A.J., MacKenna B., Inglesby P., Tomlinson L., Rentsch C.T., Curtis H.J., et al. Clinical coding of long COVID in English primary care: a federated analysis of 58 million patient records in situ using OpenSAFELY. Br J Gen Pract. 2021;71:e806&#x2013;e814.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8340730</ArticleId><ArticleId IdType="pubmed">34340970</ArticleId></ArticleIdList></Reference><Reference><Citation>Willans R., Allsopp G., Jonsson P., Glen F., Macleod J., Wei Y.H., et al. Primary care post-COVID syndrome diagnosis and referral coding. medRxiv. 2023 doi: 10.1101/2023.05.23.23289798.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2023.05.23.23289798</ArticleId></ArticleIdList></Reference><Reference><Citation>Tenforde M.W., Kim S.S., Lindsell C.J., Billig Rose E., Shapiro N.I., Files D.C., et al. Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network &#x2013; United States. MMWR Morb Mortal Wkly Rep. 2020;69:993&#x2013;998.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7392393</ArticleId><ArticleId IdType="pubmed">32730238</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S., Quan L., Chavarro J.E., Slopen N., Kubzansky L.D., Koenen K.C., et al. Associations of depression, anxiety, worry, perceived stress, and loneliness prior to infection with risk of post&#x2013;COVID-19 conditions. JAMA Psychiatry. 2022;79:1081&#x2013;1091.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9453634</ArticleId><ArticleId IdType="pubmed">36069885</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitton R., Sweetman J., Heseltine-Carp W., van der Feltz-Cornelis C. Anti-inflammatory medications for the treatment of mental disorders: a scoping review. Brain Behav Immun Health. 2022;26</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9547233</ArticleId><ArticleId IdType="pubmed">36217374</ArticleId></ArticleIdList></Reference><Reference><Citation>American Psychiatric Association . American Psychiatric Association; Arlington: 2013. Diagnostic and Statistical Manual of Mental Disorders (DSM&#x2013;5)</Citation></Reference><Reference><Citation>van der Feltz-Cornelis C., Turk F., Sweetman J., Khunti K., Gabbay M., Shepherd J., et al. Prevalence of mental health conditions and brain fog in people with long COVID: a systematic review and meta-analysis. Gen Hosp Psychiatry. 2024;88:10&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">38447388</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-de-Las-Pe&#xf1;as C., G&#xf3;mez-Mayordomo V., Garc&#xed;a-Azor&#xed;n D., Palacios-Ce&#xf1;a D., Florencio L.L., Guerrero A.L., et al. Previous history of migraine is associated with fatigue, but not headache, as long-term post-COVID symptom after severe acute respiratory SARS-CoV-2 infection: a case-control study. Front Hum Neurosci. 2021;15</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8290894</ArticleId><ArticleId IdType="pubmed">34295230</ArticleId></ArticleIdList></Reference><Reference><Citation>Magdy R., Elmazny A., Soliman S.H., Elsebaie E.H., Ali S.H., Abdel Fattah A.M., et al. Post-COVID-19 neuropsychiatric manifestations among COVID-19 survivors suffering from migraine: a case-control study. J Headache Pain. 2022;23:101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9372973</ArticleId><ArticleId IdType="pubmed">35962348</ArticleId></ArticleIdList></Reference><Reference><Citation>Coomes E.A., Haghbayan H. Interleukin-6 in Covid-19: a systematic review and meta-analysis. Rev Med Virol. 2020;30:1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7460877</ArticleId><ArticleId IdType="pubmed">32845568</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharifkashani S., Bafrani M.A., Khaboushan A.S., Pirzadeh M., Kheirandish A., Yavarpour Bali H., et al. Angiotensin-converting enzyme 2 (ACE2) receptor and SARS-CoV-2: Potential therapeutic targeting. Eur J Pharmacol. 2020;884</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7834210</ArticleId><ArticleId IdType="pubmed">32745604</ArticleId></ArticleIdList></Reference><Reference><Citation>Shabnam S., Razieh C., Dambha-Miller H., Yates T., Gillies C., Chudasama Y.V., et al. Socioeconomic inequalities of Long COVID: a retrospective population-based cohort study in the United Kingdom. J R Soc Med. 2023;116:263&#x2013;273.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10469969</ArticleId><ArticleId IdType="pubmed">37164035</ArticleId></ArticleIdList></Reference><Reference><Citation>Baz S.A., Fang C., Carpentieri J.D., Sheard L. &#x2018;I don&#x2019;t know what to do or where to go&#x2019;. Experiences of accessing healthcare support from the perspectives of people living with Long Covid and healthcare professionals: a qualitative study in Bradford, UK. Health Expect Int J Public Particip Health Care Health Policy. 2023;26:542&#x2013;554.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10124541</ArticleId><ArticleId IdType="pubmed">36512382</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy H., Janke A. Health Literacy and Access to Care. J Health Commun. 2016;21:43&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4924568</ArticleId><ArticleId IdType="pubmed">27043757</ArticleId></ArticleIdList></Reference><Reference><Citation>Crook H., Raza S., Nowell J., Young M., Edison P. Long covid-mechanisms, risk factors, and management. BMJ. 2021;374:n1648.</Citation><ArticleIdList><ArticleId IdType="pubmed">34312178</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulchandani R., Lyngdoh T., Kakkar A.K. Deciphering the COVID-19 cytokine storm: systematic review and meta-analysis. Eur J Clin Invest. 2021;51</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7646004</ArticleId><ArticleId IdType="pubmed">33058143</ArticleId></ArticleIdList></Reference><Reference><Citation>Baksh R.A., Strydom A., Pape S.E., Chan L.F., Gulliford M.C. Susceptibility to COVID-19 diagnosis in people with down syndrome compared to the general population: matched-cohort study using primary care electronic records in the UK. J Gen Intern Med. 2022;37:2009&#x2013;2015.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8985744</ArticleId><ArticleId IdType="pubmed">35386043</ArticleId></ArticleIdList></Reference><Reference><Citation>Clinical Practice Research Datalink. Availability of CPRD linked data; 2023. &#x2329;https://www.cprd.com/cprd-linked-data&#x232a;.</Citation></Reference><Reference><Citation>Ledford H. How common is long COVID? Why studies give different answers. Nature. 2022;606:852&#x2013;853.</Citation><ArticleIdList><ArticleId IdType="pubmed">35725828</ArticleId></ArticleIdList></Reference><Reference><Citation>Khunti K., Banerjee A., Evans R.A., Calvert M. Long COVID research in minority ethnic populations may be lost in translation. Nat Med. 2024:1&#x2013;2. doi: 10.1038/s41591-024-03070-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-024-03070-y</ArticleId><ArticleId IdType="pubmed">38918633</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>